These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19236508)

  • 1. Down-regulated expression of the TSAP6 protein in liver is associated with a transition from cirrhosis to hepatocellular carcinoma.
    Caillot F; Daveau R; Daveau M; Lubrano J; Saint-Auret G; Hiron M; Goria O; Scotte M; Francois A; Salier JP
    Histopathology; 2009 Feb; 54(3):319-27. PubMed ID: 19236508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver.
    Masaki T; Tokuda M; Yoshida S; Nakai S; Morishita A; Uchida N; Funaki T; Kita Y; Funakoshi F; Nonomura T; Himoto T; Deguchi A; Kimura Y; Izuishi K; Wakabayashi H; Usuki H; Yoshiji H; Watanabe S; Kurokohchi K; Kuriyama S
    Int J Oncol; 2005 Mar; 26(3):661-71. PubMed ID: 15703821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global gene repression in hepatocellular carcinoma and fetal liver, and suppression of dudulin-2 mRNA as a possible marker for the cirrhosis-to-tumor transition.
    Coulouarn C; Derambure C; Lefebvre G; Daveau R; Hiron M; Scotte M; François A; Daveau M; Salier JP
    J Hepatol; 2005 Jun; 42(6):860-9. PubMed ID: 15885357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
    Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
    Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence.
    Caillot F; Derambure C; Bioulac-Sage P; Francois A; Scotte M; Goria O; Hiron M; Daveau M; Salier JP
    World J Gastroenterol; 2009 Jan; 15(3):300-9. PubMed ID: 19140229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic alteration of the SOCS1 gene in hepatocellular carcinoma.
    Chu PY; Yeh CM; Hsu NC; Chang YS; Chang JG; Yeh KT
    Swiss Med Wkly; 2010; 140():w13065. PubMed ID: 20648401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
    Koskinas J; Petraki K; Kavantzas N; Rapti I; Kountouras D; Hadziyannis S
    J Viral Hepat; 2005 Nov; 12(6):635-41. PubMed ID: 16255765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical detection of ras oncogene p21 product in liver cirrhosis and hepatocellular carcinoma.
    Nonomura A; Ohta G; Hayashi M; Izumi R; Watanabe K; Takayanagi N; Mizukami Y; Matsubara F
    Am J Gastroenterol; 1987 Jun; 82(6):512-8. PubMed ID: 3034055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA Expression in Focal Nodular Hyperplasia in Comparison with Cirrhosis and Hepatocellular Carcinoma.
    Lendvai G; Szekerczés T; Gyöngyösi B; Schlachter K; Kontsek E; Pesti A; Patonai A; Werling K; Kovalszky I; Schaff Z; Kiss A
    Pathol Oncol Res; 2019 Jul; 25(3):1103-1109. PubMed ID: 30411298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SH2D4A is frequently downregulated in hepatocellular carcinoma and cirrhotic nodules.
    Quagliata L; Andreozzi M; Kovac M; Tornillo L; Makowska Z; Moretti F; Heim MH; Heinimann K; Piscuoglio S; Terracciano LM
    Eur J Cancer; 2014 Mar; 50(4):731-8. PubMed ID: 24315626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
    Nardone G; Romano M; Calabrò A; Pedone PV; de Sio I; Persico M; Budillon G; Bruni CB; Riccio A; Zarrilli R
    Hepatology; 1996 Jun; 23(6):1304-12. PubMed ID: 8675143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow cytometric DNA analysis of cirrhotic liver cells in patients with hepatocellular carcinoma can provide a new prognostic factor.
    Ruà S; Comino A; Fruttero A; Torchio P; Bouzari H; Taraglio S; Torchio B; Capussotti L
    Cancer; 1996 Sep; 78(6):1195-202. PubMed ID: 8826940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma.
    Hsu DK; Dowling CA; Jeng KC; Chen JT; Yang RY; Liu FT
    Int J Cancer; 1999 May; 81(4):519-26. PubMed ID: 10225438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fractional allelic loss in non-end-stage cirrhosis: correlations with hepatocellular carcinoma development during follow-up.
    Roncalli M; Bianchi P; Grimaldi GC; Ricci D; Laghi L; Maggioni M; Opocher E; Borzio M; Coggi G
    Hepatology; 2000 Apr; 31(4):846-50. PubMed ID: 10733538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small Nucleolar RNA Host Gene 18 Acts as a Tumor Suppressor and a Diagnostic Indicator in Hepatocellular Carcinoma.
    Liu XF; Thin KZ; Ming XL; Shuo-Li ; Ping-Luo ; Man-Zhu ; Li ND; Tu JC
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818794494. PubMed ID: 30126319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of augmenter of liver regeneration (ALR) in human liver cirrhosis and carcinoma.
    Thasler WE; Schlott T; Thelen P; Hellerbrand C; Bataille F; Lichtenauer M; Schlitt HJ; Jauch KW; Weiss TS
    Histopathology; 2005 Jul; 47(1):57-66. PubMed ID: 15982324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver cell dysplasia in normal, cirrhotic, and hepatocellular carcinoma patients.
    Cohen C; Berson SD
    Cancer; 1986 Apr; 57(8):1535-8. PubMed ID: 3004693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Regulation of p53 and bcl-2 proteins to apoptosis and cell proliferation in liver cirrhosis and hepatocellular carcinoma].
    Feng D; Zheng H; Shen M; Cheng R; Yan Y
    Hunan Yi Ke Da Xue Xue Bao; 1999; 24(4):325-8. PubMed ID: 12080637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
    Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
    Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 expression in patients with cirrhosis with and without hepatocellular carcinoma.
    Livni N; Eid A; Ilan Y; Rivkind A; Rosenmann E; Blendis LM; Shouval D; Galun E
    Cancer; 1995 May; 75(10):2420-6. PubMed ID: 7736384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.